CDK2 and cancer: RB1 is frequently mutated in a number of cancers (7% in total, according to TCGA database), including sarcoma, bladder, endometrial, ovarian, breast, prostate and non-small cell lung (NSCLC) cancers, and the Rb protein is inactivated by high CDK4/6 or CDK2 activity [32,56,57].